Cargando…
COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19
The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an eas...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484553/ https://www.ncbi.nlm.nih.gov/pubmed/34593915 http://dx.doi.org/10.1038/s41598-021-98812-0 |
_version_ | 1784577342573641728 |
---|---|
author | Menestrina, Luca Cabrelle, Chiara Recanatini, Maurizio |
author_facet | Menestrina, Luca Cabrelle, Chiara Recanatini, Maurizio |
author_sort | Menestrina, Luca |
collection | PubMed |
description | The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an easy-to-use, freely accessible online tool. Starting from this consideration, we developed COVIDrugNet (http://compmedchem.unibo.it/covidrugnet), a web application that allows users to capture a holistic view and keep up to date on how the clinical drug research is responding to the SARS-CoV-2 infection. Here, we describe the web app and show through some examples how one can explore the whole landscape of medicines in clinical trial for the treatment of COVID-19 and try to probe the consistency of the current approaches with the available biological and pharmacological evidence. We conclude that careful analyses of the COVID-19 drug-target system based on COVIDrugNet can help to understand the biological implications of the proposed drug options, and eventually improve the search for more effective therapies. |
format | Online Article Text |
id | pubmed-8484553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84845532021-10-04 COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 Menestrina, Luca Cabrelle, Chiara Recanatini, Maurizio Sci Rep Article The COVID-19 pandemic poses a huge problem of public health that requires the implementation of all available means to contrast it, and drugs are one of them. In this context, we observed an unmet need of depicting the continuously evolving scenario of the ongoing drug clinical trials through an easy-to-use, freely accessible online tool. Starting from this consideration, we developed COVIDrugNet (http://compmedchem.unibo.it/covidrugnet), a web application that allows users to capture a holistic view and keep up to date on how the clinical drug research is responding to the SARS-CoV-2 infection. Here, we describe the web app and show through some examples how one can explore the whole landscape of medicines in clinical trial for the treatment of COVID-19 and try to probe the consistency of the current approaches with the available biological and pharmacological evidence. We conclude that careful analyses of the COVID-19 drug-target system based on COVIDrugNet can help to understand the biological implications of the proposed drug options, and eventually improve the search for more effective therapies. Nature Publishing Group UK 2021-09-30 /pmc/articles/PMC8484553/ /pubmed/34593915 http://dx.doi.org/10.1038/s41598-021-98812-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Menestrina, Luca Cabrelle, Chiara Recanatini, Maurizio COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 |
title | COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 |
title_full | COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 |
title_fullStr | COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 |
title_full_unstemmed | COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 |
title_short | COVIDrugNet: a network-based web tool to investigate the drugs currently in clinical trial to contrast COVID-19 |
title_sort | covidrugnet: a network-based web tool to investigate the drugs currently in clinical trial to contrast covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484553/ https://www.ncbi.nlm.nih.gov/pubmed/34593915 http://dx.doi.org/10.1038/s41598-021-98812-0 |
work_keys_str_mv | AT menestrinaluca covidrugnetanetworkbasedwebtooltoinvestigatethedrugscurrentlyinclinicaltrialtocontrastcovid19 AT cabrellechiara covidrugnetanetworkbasedwebtooltoinvestigatethedrugscurrentlyinclinicaltrialtocontrastcovid19 AT recanatinimaurizio covidrugnetanetworkbasedwebtooltoinvestigatethedrugscurrentlyinclinicaltrialtocontrastcovid19 |